RCUS Q2 2020 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RCUSArcus Biosciences, Inc.

$2B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+0.0% YoY

Gross Profit

$2M100.0% margin

Operating Income

-$45M-2592.9% margin

Net Income

-$45M-2575.7% margin

EPS (Diluted)

$-0.93

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$24M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$481M

Total Liabilities

$53M

Stockholders' Equity

$429M

Cash & Equivalents

$285M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$2M	+0.0%
Gross Profit	$2M	$2M	+0.0%
Operating Income	-$45M	-$29M	-55.6%
Net Income	-$45M	-$28M	-60.5%